[PPSB].
PPSB, the plasma derivative which contains the vitamin K-dependent clotting factors, was first produced in 1959 at the Centre National de Transfusion Sanguine in Paris under the leadership of Jean-Pierre Soulier. Today over 20 such products are manufactured around the world. All production methods take advantage of the common adsorption and elution properties of all the vitamin K-dependent clotting factors due to the presence of gamma carboxy residues. Although the clinical use of PPSB has been extended to all congenital and acquired deficiencies of the vitamin K-dependent clotting factors and more recently to treat hemorrhagic episodes of hemophilia A patients with antibody to Factor VIII, the major clinical indication remains hemophilia B. The major complication associated with the use of PPSB is the occurrence of viral diseases, particularly non-A, non-B hepatitis of unknown etiology and specifically associated with the use of PPSB is the occurrence in some patients of thromboembolic complications. Current research is oriented toward the production of a safer product.
D001779:Blood Coagulation Factors / Q000008:administration & dosage / Q000302:isolation & purification / Q000592:standards; D001803:Blood Transfusion / Q000266:history; D004211:Disseminated Intravascular Coagulation / Q000209:etiology; D004340:Drug Contamination / Q000517:prevention & control; D005602:France; D006207:Half-Life; D002836:Hemophilia B / Q000150:complications / Q000628:therapy*; D006525:Hepatitis, Viral, Human / Q000209:etiology; D049673:History, 20th Century; D006801:Humans; D012015:Reference Standards; D013927:Thrombosis / Q000209:etiology; D065227:Transfusion Reaction
D001779:Blood Coagulation Factors; C025667:prothrombin complex concentrates
Le PPSB.